Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/16040
Título
Meningococcal disease in North America: Updates from the Global Meningococcal Initiative
Autor(es)
Asturias, Edwin J | Bai, Xilian | Bettinger, Julie A | Borrow, Ray | Castillo, Delia Nais | Caugant, Dominique A | Chacon, Grettel Chanto | Dinleyici, Ener Cagri | Echaniz-Aviles, Gabriela | Garcia, Luis | Glennie, Linda | Harrison, Lee H | Howie, Rebecca L | Itsko, Mark | Lucidarme, Jay | Oliva Marin, Jose Eduardo | Marjuki, Henju | McNamara, Lucy A | Mustapha, Mustapha M | Robinson, Joan L | Romeu, Belkis | Sadarangani, Manish | Sáez-Llorens, Xavier | Sáfadi, Marco A P | Stephens, David S | Stuart, James M | Taha, Muhamed-Kheir | Tsang, Raymond S W | Vazquez-Moreno, Julio Alberto ISCIII | De Wals, Philippe
Fecha de publicación
2022-12
Cita
J Infect. 2022 Dec;85(6):611-622.
Idioma
Inglés
Tipo de documento
journal article
Resumen
This review summarizes the recent Global Meningococcal Initiative (GMI) regional meeting, which explored meningococcal disease in North America. Invasive meningococcal disease (IMD) cases are documented through both passive and active surveillance networks. IMD appears to be decreasing in many areas, such as the Dominican Republic (2016: 18 cases; 2021: 2 cases) and Panama (2008: 1 case/100,000; 2021: <0.1 cases/100,000); however, there is notable regional and temporal variation. Outbreaks persist in at-risk subpopulations, such as people experiencing homelessness in the US and migrants in Mexico. The recent emergence of β-lactamase-positive and ciprofloxacin-resistant meningococci in the US is a major concern. While vaccination practices vary across North America, vaccine uptake remains relatively high. Monovalent and multivalent conjugate vaccines (which many countries in North America primarily use) can provide herd protection. However, there is no evidence that group B vaccines reduce meningococcal carriage. The coronavirus pandemic illustrates that following public health crises, enhanced surveillance of disease epidemiology and catch-up vaccine schedules is key. Whole genome sequencing is a key epidemiological tool for identifying IMD strain emergence and the evaluation of vaccine strain coverage. The Global Roadmap on Defeating Meningitis by 2030 remains a focus of the GMI.
Palabras clave
Antibiotic resistance | Meningitis | Meningococcal | Neisseria species | North America | Vaccination
MESH
Meningococcal Infections | Meningococcal Vaccines | Neisseria meningitidis | Meningitis, Meningococcal | Humans | Incidence | Vaccines, Conjugate
Versión en línea
DOI
Aparece en las colecciones